FDA Announces Recall of Nostrilla Nasal Decongestant Spray
October 21, 2011
The U.S. Food and Drug Administration (FDA) has notified consumers of a nationwide recall of one lot of Nostrilla Nasal Decongestant nasal spray, manufactured by Insight Pharmaceuticals, LLC.
Insight initiated the voluntary recall because of concerns that one lot (about 34,000 bottles) of the nasal spray may contain the bacteria Burkholderia cepacia (B. cepacia).
B. cepacia may cause serious infection in individuals with compromised immune systems or chronic lung infections, including people with cystic fibrosis.
The company has recalled Nostrilla Nasal Decongestant, lot #11G075, UPC Code 6373673005.
The product comes in a 1/2-ounce plastic bottle marked with lot #11G075 on the label and with an expiration date of 05/2014 stamped on the side. The recalled lot was distributed through retail outlets and pharmacies.
Consumers who have purchased Nostrilla Nasal Decongestant, lot #11G075, are urged to return the product and contact the company at 1-877-546-9059, 9 a.m. – 5 p.m. (Eastern time), Monday through Friday.
People with CF who have used the product should contact their CF physician or health care provider.
For more information on the recall, read the FDA’s announcement, which contains the manufacturer’s press release.